PTH(1-34) Analog (Generic Teriparatide)
Also known as: Teriparatide analog, PTH (1-34)
PTH(1-34) Analog (Generic Teriparatide), also called Teriparatide analog or PTH (1-34), is a PTH fragment in the PTH1 receptor agonist class. This entry covers generic and compounded preparations of the parathyroid hormone(1-34) fragment, the same active sequence as teriparatide.
For research use only.
Key Facts
- CAS
- 52232-67-4
- Molecular Weight (MW)
- ≈4118 g/mol
- Half-life
- About 1 hour after subcutaneous injection (Forteo label)
- FDA status
- Not Approved
- Evidence level
- FDA Approved
- Human dose established
- Yes
- Administration Route
- Subcutaneous
- Frequency
- Once daily
- Last updated
- Nov 7, 2026
- Reviewed
- Nov 7, 2026
- Targets
- PTH1 receptor
Research summary
PTH(1–34) analog class. The FDA-approved drug is teriparatide (Forteo/Bonsity). Research or compounded vials are not those products.
Research evidence
- Regulatory review (FDA label)3 reviewed sources
- Controlled human trials1 reviewed source
- Early or uncontrolled human studiesNone in reviewed sources
- Lab & animal studiesNone in reviewed sources
How it works
Each step shows whether the sources Peptide Library has reviewed include that kind of research. Counts are reviewed sources, not every study ever published. Reviews and programme summaries that describe human use are shown as "reported", not as trials, and registered trials without published results are listed but not counted. A higher step means research has progressed further; it does not mean a compound works better or is safer. Compounds whose evidence has not been reviewed yet show "Not reviewed" instead of a guess.
Peptide Library's PTH(1-34) Analog (Generic Teriparatide) profile summarises 3 cited studies listed in the Science section, the compound's regulatory status, and research-protocol parameters reported for it. It is a research reference, not medical advice.
PTH(1-34) Analog (Generic Teriparatide) dosage evidence
PTH(1-34) has an FDA-approved human dosage only as teriparatide, 20 mcg once daily by subcutaneous injection for osteoporosis at high risk for fracture; Forteo and teriparatide labels from other companies give the same dose. This profile covers generic, compounded and research PTH(1-34) preparations, and research or compounded vials are not FDA-approved and are not the labelled products. No label covers fracture or injury healing.
| Human dosing established | Yes |
|---|---|
| Studied dose range | 20 mcg once daily (approved teriparatide products) |
| Route | Subcutaneous |
| Frequency | Once daily |
| Duration studied | Up to 2 years in a lifetime as a rule; longer only if fracture risk remains or returns to high (teriparatide labels) |
| Half-life | About 1 hour after subcutaneous injection (Forteo label) |
| Evidence level | FDA Approved |
| Last reviewed | 2026-11-07 |
Research-reported dosing
Doses as studied, one row per regimen. Different trials used different regimens; they are listed separately rather than averaged.
| Study / context | Population | Dose | Route | Frequency | Duration | Outcome studied | Source |
|---|---|---|---|---|---|---|---|
| FDA label — Teriparatide Injection (Teva), osteoporosisFDA-approved label · FDA prescribing information | Postmenopausal women with osteoporosis at high risk for fracture; men with primary or hypogonadal osteoporosis at high risk; men and women with glucocorticoid-induced osteoporosis at high risk | 20 mcg | Subcutaneous, thigh or abdomen | Once daily | More than 2 years in a lifetime only if fracture risk remains or returns to high | Treatment of osteoporosis | Teriparatide Injection (Teva) — FDA prescribing information, DailyMed |
| FDA label — Teriparatide Injection (Alvogen), osteoporosisFDA-approved label · FDA prescribing information | The same three osteoporosis populations | 20 mcg | Subcutaneous, thigh or abdomen | Once daily | More than 2 years in a lifetime only if fracture risk remains or returns to high | Treatment of osteoporosis | Teriparatide Injection (Alvogen) — FDA prescribing information, DailyMed |
| FDA label — Forteo, osteoporosisFDA-approved label · FDA prescribing information | Postmenopausal women with osteoporosis at high risk for fracture; men with primary or hypogonadal osteoporosis at high risk; men and women with glucocorticoid-induced osteoporosis at high risk | 20 mcg | Subcutaneous, thigh or abdomen; not intravenous or intramuscular | Once daily | More than 2 years in a lifetime only if fracture risk remains or returns to high | In the label's postmenopausal study (1637 women), new vertebral fractures occurred in 5.0% with 20 mcg daily against 14.3% with placebo | FORTEO (teriparatide injection) — FDA prescribing information, DailyMed |
| Distal radius fracture healing — randomised trial of teriparatide (Aspenberg et al., 2010)Clinical trial · Randomised double-blind placebo-controlled trial | Postmenopausal women aged 45 to 85 with a distal radial fracture treated by closed reduction without surgery (n=102) | 20 mcg or 40 mcg, against placebo | Injection; route not stated in the indexed abstract | Once daily, started within 10 days of the fracture | 8 weeks | The primary hypothesis, that 40 mcg would shorten the time to cortical bridging, was not supported; in post hoc analysis healing was faster with 20 mcg than placebo (median 7.4 vs 9.1 weeks), which the authors say should be interpreted with caution | Aspenberg P et al. Teriparatide for acceleration of fracture repair in humans: a prospective, randomized, double-blind study of 102 postmenopausal women with distal radial fractures. J Bone Miner Res. 2010. |
Where sources disagree
- Teriparatide has the same sequence as the first 34 amino acids of human parathyroid hormone; the labels describe Forteo and Alvogen's product as recombinant and Teva's as chemically synthesised. The FDA-approved products (Forteo and the Teva, Alvogen and other teriparatide injections on DailyMed) are prefilled pens of 560 mcg in 2.24 mL that deliver 28 daily doses of 20 mcg. A PTH(1-34) powder vial sold for research or made by a compounder is not one of these products: its identity, content and sterility are not covered by the labels, and the labels' regimens do not describe it.
- DailyMed also lists teriparatide acetate as a bulk powder from an ingredient supplier. That listing is a raw material, not a finished medicine with a dosage.
- The teriparatide labels list osteosarcoma under Warnings and Precautions (seen in rats; reported in patients after marketing, without an increased risk in human observational studies) and say to avoid it in people at higher baseline risk, such as those with open growth plates, Paget's disease, bone metastases or prior skeletal radiation. They also warn about hypercalcaemia and orthostatic hypotension.
- Bone or injury healing is not an approved use. In the randomised fracture trial cited here, 40 mcg daily did not significantly shorten healing against placebo and only a post hoc comparison favoured 20 mcg. See the teriparatide profile for the approved product, and abaloparatide for the related PTHrP analogue, which is a different molecule with its own label.
Reconstitution
These figures are arithmetic only — they convert a vial and a volume into a concentration. They are not a recommendation to take any dose.
Calculate reconstitution & dose →Handling & administration
- Timing Notes
- Used experimentally in bone-regeneration research.
Sequence & molecular data
| Molecular formula | C181H291N55O51S2 |
|---|---|
| Molecular weight | ≈4118 g/mol |
| CAS number | 52232-67-4 |
| Half-life | ~1 h (sc); same as Forteo reference |
| Appearance | White lyophilized powder or solution (compounding form) |
| Formulation | Lyophilized Powder |
| PubChem CID | 16133850 |
| FDA UNII | 10T9CSU89I |
Identifiers link to the public PubChem, FDA Substance Registration (UNII), ChEMBL and DrugBank records for the same entity.
Science
Mechanism of Action
This entry covers generic and compounded preparations of the parathyroid hormone(1-34) fragment, the same active sequence as teriparatide. The pharmacology is the receptor biology of PTH1: intermittent daily exposure increases osteoblast number and survival and produces net bone formation, whereas continuous elevation shifts the balance toward RANKL-mediated osteoclastic resorption and bone loss. The distinction between the approved product and compounded material is not pharmacological but one of manufacturing, characterisation and regulatory oversight, and identity and purity of non-approved preparations are not assured.
Origin
Synthetic PTH(1–34).
Targets
Studies
- PTH1 receptor agonists for fracture risk: a systematic review and network meta-analysis (class-level)
- Clinical effects of teriparatide, abaloparatide, and romosozumab in postmenopausal osteoporosis (class-level)
- Effectiveness and Safety of Treatments to Prevent Fractures in People With Low Bone Mass or Primary Osteoporosis (class-level)
Regulatory & research status
PTH(1-34) Analog (Generic Teriparatide) is not an FDA-approved product. It is sold for laboratory research and has no approved medical use.
| FDA status | Not Approved |
|---|---|
| Availability | Research-Only |
| WADA (sport) | Unknown / Not Listed |
| Library classification | Research-Only |
How FDA approval, compounding and research-only status differ
Benefits
PTH(1-34) Analog (Generic Teriparatide) side effects
The effects below are drawn from PTH(1-34) Analog (Generic Teriparatide)'s prescribing information, which lists the full adverse-reaction data.
Side Effects
- Hypercalcemia
- Orthostasis
- Leg cramps
Storage & stability
Lyophilized (freeze-dried) peptide powder is far more stable than the reconstituted solution. Keep sealed vials cold, dry and away from light; long-term storage is typically frozen, with short-term refrigeration for vials in use.
Once reconstituted in bacteriostatic water, keep the solution refrigerated, avoid repeated freeze–thaw cycles and agitation, and label the vial with the reconstitution date and concentration. Discard any solution that turns cloudy or shows particulates.
Degradation rates differ by sequence: peptides containing methionine, cysteine, asparagine or glutamine are more prone to oxidation and deamidation, so shelf life after reconstitution is compound-specific rather than universal.
Read the full guide: how to store peptides before and after reconstitution →
Source: Manning MC, Chou DK, Murphy BM, Payne RW, Katayama DS. Stability of protein pharmaceuticals: an update. Pharm Res. 2010;27(4):544–575. (PMID 20143256). General guidance for research handling; not product-specific instructions.
PTH(1-34) Analog (Generic Teriparatide): frequently asked questions
What is PTH(1-34) Analog (Generic Teriparatide)?
PTH(1–34) analog class. The FDA-approved drug is teriparatide (Forteo/Bonsity). Research or compounded vials are not those products.
How does PTH(1-34) Analog (Generic Teriparatide) work?
This entry covers generic and compounded preparations of the parathyroid hormone(1-34) fragment, the same active sequence as teriparatide. The pharmacology is the receptor biology of PTH1: intermittent daily exposure increases osteoblast number and survival and produces net bone formation, whereas continuous elevation shifts the balance toward RANKL-mediated osteoclastic resorption and bone loss.
Is PTH(1-34) Analog (Generic Teriparatide) FDA approved?
No. PTH(1-34) Analog (Generic Teriparatide) is not approved by the FDA for any indication and is categorised as research-only. It has not been reviewed for safety or efficacy as a medicine, and published research should be read as investigation rather than established use.
What is the half-life of PTH(1-34) Analog (Generic Teriparatide)?
Reported half-life for PTH(1-34) Analog (Generic Teriparatide) is ~1 h (sc); same as Forteo reference. Half-life describes how long the compound persists in circulation, not how long any effect lasts, and published figures vary with route of administration, formulation and the population studied.
What peptides are similar to PTH(1-34) Analog (Generic Teriparatide)?
Compounds most often compared with PTH(1-34) Analog (Generic Teriparatide) include Teriparatide, Abaloparatide, BPC-157 and Cardiogen. They are grouped by shared mechanism or research area rather than by equivalence, and their regulatory status and evidence base differ.
References
- Class-level evidence — PTH1 receptor agonists for fracture risk: a systematic review and network meta-analysis. Osteoporos Int, 2025External reference
- Class-level evidence — Clinical effects of teriparatide, abaloparatide, and romosozumab. J Bone Miner Metab, 2025External reference
- Class-level evidence — Effectiveness and Safety of Treatments to Prevent Fractures. Ann Intern Med, 2023External reference
Related research, comparisons & guides
Related peptides
Compiled by Peptide Library Editorial · Reviewed Aug 30, 2026 · Updated Nov 7, 2026 · Version 3
This PTH(1-34) Analog (Generic Teriparatide) profile is compiled from published literature (3 cited studies linked above), public regulatory records and chemical registries. It describes what research reports; it is not medical advice, and nothing here is a dosing recommendation for humans. Peptide Library does not sell peptides. Editorial policy · How profiles are compiled · Report an error
Track PTH(1-34) Analog (Generic Teriparatide) research, inventory and reconstitution in the free Peptide Library app. Get the app for iOS or Android →